Boehringer Ingelheim’s survodutide shows breakthrough improvement in liver fibrosis with no worsening of MASH in 64.5% of patients with F2 and F3 fibrosis
Globe Newswire7-06-2024, 15:30
Matrix Service Company Updates Timing for Release of 8-02-2023, 04:15